Şahika Zeynep Akı

Şahika Zeynep Akı

Auto-generated profile, based on publicly available information

Şahika Zeynep Akı

Ankara Etlik Şehir Hastanesi

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Hematology
Verified
Journal Article
Closed access
MYMünci Yağcı
Münci Yağcı
ZÖZübeyde Nur Özkurt
Zübeyde Nur Özkurt
ZYZeynep Arzu Yeğin
Zeynep Arzu Yeğin
ZAZeynep Akı
Zeynep Akı
GSGülsan Türköz Sucak
Gülsan Türköz Sucak
RHRauf Haznedar
Rauf Haznedar
Reactivation of hepatitis B virus (HBV) is a frequent complication of chemotherapy (CT) in patients with HBsAg carriers. In this prospective study, we documented CT induced HBV reactivation risk in patients with hematological malignancies. HBV reactivation risk is influenced by baseline viral load. Therefore, we divided our study population into two groups according to HBV-DNA status. HBV-DNA negative patients (n=18) were treated with nucleoside analogues once HBV reactivation was observed. HBV-DNA positive patients (n=12) commenced lamivudine before the initiation of the CT. In HBV-DNA negative patients HBV reactivation was found in 10 patients (55.5%). HBV reactivation was significantly more frequent in chronic lymphocytic leukemia (CLL) patients (P=0.008) and in patients receiving rituximab containing chemotherapy regimens (P=0.06). Eight patients (80.0%) responded to antiviral treatment after HBV reactivation. Two CLL patients experienced a flare-up after the withdrawal of antiviral therapy. In HBV-DNA positive patients, HBV reactivation was observed in four patients (33.3%) during lamivudine treatment and in two patients after lamivudine withdrawal. This study demonstrated the increased risk of CT-induced HBV reactivation in CLL patients, for the first time.


1 December 2020 in Journal of Infection
Verified
Journal Article
Closed access
DADiana Averbuch
Diana Averbuch
GTGloria Tridello
Gloria Tridello
JHJennifer Hoek
Jennifer Hoek
MMMalgorzata Mikulska
Malgorzata Mikulska
Thomas PabstThomas Pabst
Thomas Pabst
SCSimone Cesaro
Simone Cesaro

21 April 2018 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
ŞAŞahika Zeynep Akı
Şahika Zeynep Akı
GSGülsan Türköz Sucak
Gülsan Türköz Sucak
ÖTÖzlem Güzel Tunçcan
Özlem Güzel Tunçcan
NKNurdan Köktürk
Nurdan Köktürk
EŞEsin Şenol
Esin Şenol

1 January 2008 in Neurology India
Verified
Journal Article
Open access
PDF file
ZAZeynep Aki
Zeynep Aki
ÖAÖzlem Yüksel Aksoy
Özlem Yüksel Aksoy
GSGulsan Sucak
Gulsan Sucak
RKReha Kuruoglu
Reha Kuruoglu
MYMunci Yagci
Munci Yagci
Chronic lymphocytic leukemia (CLL) is a frequent hematological malignancy, with meningeal or peripheral nerve infiltrations being the most commonly encountered neurological complications. In this report, we describe a CLL patient with Miller-Fisher syndrome (MFS) who responded to immune modulation with plasmapheresis. A 47-year-old man diagnosed as B-cell CLL admitted with neutropenic fever. He complained of diplopia and numbness of both arms. Neurological examination revealed a bilateral external ophthalmoplegia, dysphagia, dysarthria, mild shoulder girdle muscle weakness and gait ataxia, accompanied by absent tendon reflexes. Nerve conduction studies were indicative of a predominantly axonal sensori-motor peripheral neuropathy. This association of CLL with MFS had not been previously reported in the literature.

1 September 2013 in Hematology
Verified
Journal Article
Closed access
GSGülsan Türköz Sucak
Gülsan Türköz Sucak
MÇMerih Kızıl Çakar
Merih Kızıl Çakar
ESElif Suyanı
Elif Suyanı
ZAZeynep Akı
Zeynep Akı
SASŞermin Altındal
SŞermin Altındal
KAKadir Acar
Kadir Acar
The aim of this study is to assess the predictors of outcome in patients with relapsed or refractory Hodgkin's lymphoma (HL) receiving autologous stem-cell transplantation (ASCT) MATERIALS AND METHODS: Fifty-two consecutive patients who received ASCT at the Stem Cell Transplantation Unit of Gazi University Hospital from February 2005 through June 2011 for relapsed or refractory HL were analysed retrospectively Fifty-one patients could be evaluated after transplantation, as one of the patients died in the early post-transplantation period. Complete remission was obtained in 36 (71%), partial remission in 9 (18%), stable disease in 4 (8%), and progressive disease in 2 (3%) patients. After a median follow-up of 22 (range, 0.5-75) months, 46 (88%) patients were alive. The probability of overall survival (OS), progression free survival (PFS) and transplantation related mortality at 5 years were 87, 53, and 2%, respectively. Chemosensitive relapse had a positive impact on both OS and PFS CONCLUSION: ASCT remains to be the standard treatment of relapsed or refractory HL patients. Chemosensitive relapse is the most important prognostic factor determining the outcome of the ASCT.